By Shida Chayesteh

September 19, 2014

COPENHAGEN (Reuters) - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than basal-bolus treatment, according to new data from a late-stage study.

Ryzodeg combines Tresiba, Novo Nordisk's great hope for future growth, with insulin aspart, a man-made form of insulin, also known as NovoRapid, in a single pen injector.

Novo Nordisk, the world's biggest insulin maker, has launched Ryzodeg commercially in Mexico. Analysts have estimated it has blockbuster potential which could mean sales in the billions of dollars in years to come.

The study, unveiled at a meeting of the European Association for the Study of Diabetes (EASD) in Vienna on Thursday, compared Ryzodeg with basal-bolus treatment, which in this case was Novo's Tresiba and two to four injections of Novo's NovoRapid.

After 26 weeks, both patient groups achieved good blood sugar control but the group taking Ryzodeg needed fewer injections and had fewer incidents of hypoglycemia.

The basal-bolus regimen for treating type 2 diabetes involves taking a longer-acting form of insulin to keep blood sugar levels stable through periods of fasting and separate injections of shorter-acting mealtime insulin to prevent rises in blood sugar levels.

"Patients currently using basal-bolus regimens may need to take up to four daily injections, which can be a great burden and very inconvenient," Dr Helena Rodbard, the study's lead investigator and endocrinologist in Rockville, MD, USA, said.

"Ryzodeg is a new treatment option which provides proven glycaemic control, with fewer injections and reduced rates of hypoglycaemia compared to basal-bolus regimens," Rodbard said.

Combination therapies for type 2 diabetes are becoming increasingly common as patients continually require additional medicines as the disease progresses.

With diabetes affecting 382 million people worldwide and the number of cases expected to rise to 592 million by 2035, according to the International Diabetes Federation, the disease represents a huge market for pharmaceutical companies.

The Danish company, whose main rivals include Sanofi and Eli Lilly & Co, aims to increase the number of people using its drugs to 40 million in 2020 from 23 million in 2012.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: